PDPN and neoplasm: With regard to tumor suppression, ADCC/CDC activity may be partly involved in the anti-tumor activity of the anti-podoplanin antibodies because an anti-PLAG3 mAb MS-1 of murine IgG2a subclass having strong ADCC/CDC activity, but not an anti-PLAG3 mAb P2–0 of murine IgG1 subclass exhibiting low ADCC/CDC activity, could attenuate CHO/PDPN proliferation in nude mice [23].